Welcome to our dedicated page for Zynex news (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex stock.
Zynex Inc. develops, manufactures, markets, and sells non-invasive medical devices used for pain management, rehabilitation, and patient monitoring. Company updates have focused on financial results, payer and billing procedures, revenue and cash-flow performance, sales-force changes, and product activity in patient monitoring, including pulse oximetry.
Zynex news also covers governance and corporate-status developments, including board and leadership changes, compliance initiatives, strategic alternatives, and the company's court-supervised financial restructuring. Later regulatory disclosures document that the reorganization became effective and that the prior publicly traded common stock was cancelled.
Zynex, a medical technology company, announced a public offering of its common stock. The offering involves Zynex and certain stockholders proposing to sell shares, with a 30-day option for underwriters to purchase additional shares. Funds from the offering will be used to expand the sales force, marketing efforts, and launch a new blood volume monitor. The offering is subject to market conditions, and Zynex will not receive proceeds from sales made by stockholders. Piper Sandler is the sole book-running manager for this offering.
Zynex, Inc. (NASDAQ: ZYXI), a medical technology company, reported a 37% increase in orders for Q2 2020 compared to Q2 2019, though orders were 23% lower than Q1 2020 due to COVID-19 impacts. The company updated its Q2 revenue estimate to between $18.9 million and $19.4 million, up from a previous estimate of $17.5 million to $18 million. Zynex also increased its full-year revenue estimate to between $80 million and $85 million, a projected increase of 76% to 87% over last year's revenue of $45.5 million.